The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Open accessAbstract
OBJECTIVE: Several studies have suggested an association between specific diabetes treatment and cancer mortality. We studied the association between metformin use and cancer mortality in a prospectively followed cohort. RESEARCH DESIGN AND METHODS: In 1998 and 1999, 1,353 patients with type 2 diabetes were enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) study in the Netherlands. Vital status was assessed in January 2009. Cancer mortality rate was evaluated using standardized mortality ratios (SMRs), and the association between metformin use and cancer mortality was evaluated with a Cox proportional hazards model, taking possible confounders into account. RESULTS: Median follow-up time was 9.6 years, average age at baseline was 68 years, and average A1C was 7.5%. Of the patients, 570 died, of which 122 died of malignancies. The SMR for cancer mortality was 1.47 (95% CI 1.22–1.76). In patients taking metformin compared with patients not taking metformin at baseline, the adjusted hazard ratio (HR) for cancer mortality was 0.43 (95% CI 0.23–0.80), and the HR with every increase of 1 g of metformin was 0.58 (95% CI 0.36–0.93). CONCLUSIONS: In general, patients with type 2 diabetes are at increased risk for cancer mortality. In our group, metformin use was associated with lower cancer mortality compared with nonuse of metformin. Although the design cannot provide a conclusion about causality, our results suggest a protective effect of metformin on cancer mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several epidemiologic studies have shown that metformin use is associated with reduced cancer incidence and mortality (Landman et al., 2010; Lee et al., 2011; Libby et al., 2009; Monami et al., 2011; Tseng, 2012).”
From Metformin as a tool to target aging (2016) · cites this paper as Landman et al., 2010
In the citing paper
“The reduced risk of cancer and cancer mortality observed in these studies has been consistently in the range of 25% to 30% [135-139,145-147].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“A prospective study (median follow-up time of 9.6 years) found that metformin use at baseline was associated with lower cancer-related mortality and that this association appeared to be dose dependent [138].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“Metformin use is associated with lower cancer-related mortality.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“Patients with type 2 diabetes who are prescribed metformin had a lower risk of cancer compared to patients who did not take it.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“When compared to those on other treatments, metformin users had a lower risk of cancer. A dose-relationship has been reported [138,144,145].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [138]
In the citing paper
“Results of a growing number of observational human studies suggest that treatment with metformin (relative to other glucose-lowering therapies) is associated with reduced risk of cancer (89–93) or cancer mortality (94).”
From Diabetes and Cancer (2010) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Jiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 1×
“For example, type 2 diabetic patients receiving neoadjuvant chemotherapy for breast cancer as well as metformin were more likely to have a complete remission than patients not receiving metformin (14).”
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. M., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584
Prospective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women
Hu, F. B., Manson, J. E., Liu, S., Hunter, D. J., Colditz, G. A., Michels, K. B., Speizer, F. E., & Giovannucci, E. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.542 · Cited by 420
Flagged first, then by citations
1 of the 20 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Metformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096
Diabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,082
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Wolin, K. Y., Carson, K., & Colditz, G. A. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0285 · Cited by 778
The genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 754
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G. E., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S. E., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 646
Barry, J. A., Azizia, M., & Hardiman, P. J. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu012 · Cited by 603
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033411 · Cited by 566
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Metformin and the Risk of Cancer
Suissa, S., & Azoulay, L. (2012) · Diabetes Care · doi:10.2337/dc12-0788 · Cited by 543
Metformin in Cancer Treatment and Prevention
Morales, D. R., & Morris, A. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-062613-093128 · Cited by 494
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2010) · Diabetes Care · doi:10.2337/dc09-1791 · Cited by 466
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK
Wang, Y., An, H., Liu, T., Qin, C., Sesaki, H., Guo, S., Radovick, S., Hussain, M., Maheshwari, A., Wondisford, F. E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.070 · Cited by 432
“In addition to its antidiabetic effects, metformin has received great attention because many studies have shown a reduction in cancer incidence in patients with diabetes mellitus treated with metformin (Evans et al., 2005; Landman et al., 2010; Li et al., 2009).”
BackgroundMetformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
Understanding the benefit of metformin use in cancer treatment
Dowling, R. J. O., Goodwin, P. J., & Stambolic, V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-33 · Cited by 417
The proliferating role of insulin and insulin-like growth factors in cancer
Gallagher, E. J., & LeRoith, D. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.06.007 · Cited by 398
Metformin: Taking away the candy for cancer?
Jalving, M., Gietema, J. A., Lefrandt, J. D., de Jong, S., Reyners, A. K. L., Gans, R. O. B., & de Vries, E. G. E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.012 · Cited by 382
Self-citationJustice, J. N., Ferrucci, L., Newman, A. B., Aroda, V. R., Bahnson, J. L., Divers, J., Espeland, M. A., Marcovina, S., Pollak, M. N., Kritchevsky, S. B., et al. (2018) · GeroScience · doi:10.1007/s11357-018-0042-y · Cited by 359
Metformin in cancer: translational challenges
Dowling, R. J. O., Niraula, S., Stambolic, V., & Goodwin, P. J. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0007 · Cited by 371
Saraei, P., Asadi, I., Kakar, M. A., & Moradikor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 361
Metformin: a review of its potential indications
Wang, Y., He, S., Feng, X., Cheng, J. Q., Luo, Y.-T., Tian, L., & Huang, Q. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s141675 · Cited by 330
Diabetes and pancreatic cancer
Li, D. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20771 · Cited by 318
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Sadeghi, N., Abbruzzese, J. L., Yeung, S. J., Hassan, M. M., & Li, D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2994 · Cited by 308
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D., & LeRoith, D. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0374 · Cited by 308
Metformin: Multi-faceted protection against cancer
Barco, S. D., Vázquez‐Martín, A., Cufí, S., Oliveras‐Ferraros, C., Bosch‐Barrera, J., Joven, J., Martı́n-Castillo, B., & Menéndez, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.387 · Cited by 307
Metformin and cancer: new applications for an old drug
Kourelis, T., & Siegel, R. D. (2011) · Medical Oncology · doi:10.1007/s12032-011-9846-7 · Cited by 294
Associations of Insulin Resistance and Adiponectin With Mortality in Women With Breast Cancer
Duggan, C. R., Irwin, M. L., Xiao, L., Henderson, K. D., Smith, A. W., Baumgartner, R., Baumgartner, K. B., Bernstein, L., Ballard-Barbash, R. R., & McTiernan, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4473 · Cited by 291
Bao, B., Ahmad, A., Azmi, A. S., Ali, S. S., & Sarkar, F. H. (2013) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1425s61 · Cited by 291
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G. M., Catapano, A. L., Vecchia, C. L., Mancia, G., & Corrao, G. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0462 · Cited by 276
Association of metformin use with cancer incidence and mortality: A meta-analysis
Zhang, P., Li, H., Tan, X., Chen, L., & Wang, S. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2012.12.009 · Cited by 274
Pierotti, M. A., Berrino, F., Gariboldi, M., Melani, C. C., Mogavero, A., Negri, T., Pasanisi, P., & Pilotti, S. (2012) · Oncogene · doi:10.1038/onc.2012.181 · Cited by 253
Metformin and Systemic Metabolism
He, L. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.001 · Cited by 248
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications
Greene, J. P., Segaran, A., & Lord, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.002 · Cited by 215
Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena
Martı́n-Castillo, B., Vázquez‐Martín, A., Oliveras‐Ferraros, C., & Menéndez, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.6.10994 · Cited by 215
Xu, H., Aldrich, M. C., Chen, Q., Liu, H., Peterson, N. B., Dai, Q., Levy, M. A., Shah, A., Han, X., Ruan, X., et al. (2014) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2014-002649 · Cited by 221
Zhang, H., Zhai, Z., Wang, Y., Zhang, J., Wu, H., Wang, Y., Li, C., Li, D., Lu, L., Wang, X., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.530 · Cited by 212
Chen, Y., Wu, F., Saito, E., Lin, Y., Song, M., Luu, H. N., Gupta, P. C., Sawada, N., Tamakoshi, A., Shu, X., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4229-z · Cited by 207
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation
Gallagher, E. J., & LeRoith, D. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06285.x · Cited by 208
The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus
Lee, J. H., Kim, T. I., Jeon, S. M., Hong, S. P., Cheon, J. H., & Kim, W. H. (2011) · International Journal of Cancer · doi:10.1002/ijc.26421 · Cited by 206
Current understanding of metformin effect on the control of hyperglycemia in diabetes
An, H., & He, L. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0447 · Cited by 205
Chen, G., Xu, S., Renko, K., & Derwahl, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1754 · Cited by 196
Fendt, S., Bell, E. L., Keibler, M. A., Davidson, S. M., Wirth, G. J., Fiske, B. P., Mayers, J. R., Schwab, M. G., Bellinger, G., Csibi, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0080 · Cited by 196
Tsilidis, K. K., Capothanassi, D., Allen, N. E., Rizos, E. C., López, D. S., van Veldhoven, K., Sacerdote, C., Ashby, D., Vineis, P., Tzoulaki, I., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0584 · Cited by 192
Thakkar, B., Aronis, K. N., Vamvini, M. T., Shields, K. S., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.01.014 · Cited by 188
Bi, Y., Lu, J., Wang, W., Mu, Y., Zhao, J., Liu, C., Chen, L., Shi, L., Li, Q., Wan, Q., et al. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12108 · Cited by 187
Stevens, R. J., Ali, R., Bankhead, C. R., Bethel, M. A., Cairns, B. J., Camisasca, R. P., Crowe, F. L., Farmer, A. J., Harrison, S., Hirst, J. A., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2653-7 · Cited by 161
Algire, C., Amrein, L., Bazile, M., David, S., Zakikhani, M., & Pollak, M. (2010) · Oncogene · doi:10.1038/onc.2010.483 · Cited by 186
Romero, I. L., McCormick, A., McEwen, K. A., Park, S., Karrison, T. G., Yamada, S. D., Pannain, S., & Lengyel, E. R. (2011) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e3182393ab3 · Cited by 178
Bayraktar, S., Hernadez‐Aya, L. F., Lei, X., Meric‐Bernstam, F., Litton, J. K., Hsu, L., Hortobagyi, G. N., & Gonzalez‐Angulo, A. M. (2012) · Cancer · doi:10.1002/cncr.26439 · Cited by 176
Cao, J., Meng, S., Chang, E., Beckwith-Fickas, K., Xiong, L., Cole, R. N., Radovick, S., Wondisford, F. E., & He, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.567271 · Cited by 173
Chou, C.-C., Lee, K., Lai, I., Wang, D.-S., Mo, X. M., Kulp, S. K., Shapiro, C. L., & Chen, C. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0135 · Cited by 174
Noto, H., Tsujimoto, T., Sasazuki, T., & Noda, M. (2011) · Endocrine Practice · doi:10.4158/ep10357.ra · Cited by 169
Metformin: An anti-diabetic drug to fight cancer
Daugan, M. V., Wojcicki, A. D., d’Hayer, B., & Boudy, V. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.006 · Cited by 172
Impact of Metformin on the Prognosis of Cirrhosis Induced by Viral Hepatitis C in Diabetic Patients
Nkontchou, G., Cosson, E., Aout, M., Mahmoudi, A., Bourcier, V., Charif, I., Ganne‐Carrié, N., Grando–Lemaire, V., Vicaut, É., Trinchet, J., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2415 · Cited by 167
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 173
Tan, B., Yao, W., Ge, J., Peng, X., Du, X., Zhang, R., Yao, B., Xie, K., Li, L., Dong, H., et al. (2011) · Cancer · doi:10.1002/cncr.26151 · Cited by 161
Metformin is associated with improved survival in endometrial cancer
Ko, E. M., Walter, P. J., Jackson, A. L., Clark, L. H., Franasiak, J. M., Bolac, C. S., Havrilesky, L. J., Secord, A. A., Moore, D. T., Gehrig, P. A., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.021 · Cited by 159
Use of metformin and the risk of ovarian cancer: A case–control analysis
Bodmer, M., Becker, C., Meier, C., Jick, S. S., & Meier, C. R. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.06.038 · Cited by 158
Thakur, S., Daley, B., Gaskins, K., Vasko, V. V., Boufraqech, M., Patel, D., Sourbier, C., Reece, J. M., Cheng, S.-Y., Kebebew, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3167 · Cited by 157
Rizos, C. V., & Elisaf, M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.038 · Cited by 155
Tumour metabolism and its unique properties in prostate adenocarcinoma
Bader, D. A., & McGuire, S. E. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0288-x · Cited by 162
Epidemiological aspects of neoplasms in diabetes
Nicolucci, A. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0187-3 · Cited by 154
Metformin and cancer: An existing drug for cancer prevention and therapy (Review)
Zi, F., Zi, H., Li, Y., He, J., Shi, Q., & Cai, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7412 · Cited by 156
Garrett, C. R., Hassabo, H. M., Bhadkamkar, N. A., Wen, S., Baladandayuthapani, V., Kee, B. K., Eng, C., & Hassan, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.71 · Cited by 153
New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent
Leone, A., Gennaro, E. D., Bruzzese, F., Avallone, A., & Budillon, A. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-38007-5_21 · Cited by 150
The Glycocalyx and Its Role in Vascular Physiology and Vascular Related Diseases
Weinbaum, S., Cancel, L. M., Fu, B. M., & Tarbell, J. M. (2020) · Cardiovascular Engineering and Technology · doi:10.1007/s13239-020-00485-9 · Cited by 153
Liu, B., Fan, Z., Edgerton, S. M., Yang, X., Lind, S. E., & Thor, A. D. (2011) · Cell Cycle · doi:10.4161/cc.10.17.16359 · Cited by 120
Diabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’
Cignarelli, A., Genchi, V. A., Caruso, I., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.002 · Cited by 156
Synergistic Anti-Cancer Effect of Phenformin and Oxamate
Miskimins, W. K., Ahn, H. J., Kim, J. Y., Ryu, S., Jung, Y., & Choi, J. Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085576 · Cited by 144
Lee, J. O., Kang, M. J., Byun, W. S., Kim, S. A., Seo, I. H., Han, J. A., Moon, J. W., Kim, J. H., Kim, S. J., Lee, E. J., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1204-2 · Cited by 146
Metformin for aging and cancer prevention
Anisimov, V. N. (2010) · Aging · doi:10.18632/aging.100230 · Cited by 142
Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation
Salt, I. P., & Palmer, T. M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.696609 · Cited by 141
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models
Lengyel, E. R., Litchfield, L. M., Mitra, A. K., Nieman, K. M., Mukherjee, A., Zhang, Y., Johnson, A., Bradaric, M. J., Lee, W., & Romero, I. L. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.10.026 · Cited by 137
Diabetes and cancer: Associations, mechanisms, and implications for medical practice
Xu, C. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.372 · Cited by 138
Yang, W.-S., Va, P., Bray, F., Gao, S., Gao, J., Li, H. L., & Xiang, Y.-B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027326 · Cited by 136
Metformin use and endometrial cancer survival
Nevadunsky, N. S., Arsdale, A. V., Strickler, H. D., Moadel, A. B., Kaur, G., Frimer, M., Conroy, E. M., Goldberg, G. L., & Einstein, M. H. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.10.026 · Cited by 134
COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs
Gurpinar, E., Grizzle, W. E., & Piazza, G. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00181 · Cited by 135
Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes
Azoulay, L., Dell’Aniello, S., Gagnon, B., Pollak, M., & Suissa, S. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0940 · Cited by 133
Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan
Tseng, C. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0369 · Cited by 132
Kulkarni, A. S., Aleksić, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022) · Aging Cell · doi:10.1111/acel.13596 · Cited by 132
Metformin ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice
Xu, G., Wu, H., Zhang, J., Li, D., Wang, Y., Wang, Y., Zhang, H., Lu, L., Li, C., Huang, S. M., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.045 · Cited by 132
Soares, H. P., Ni, Y., Kisfalvi, K., Sinnett‐Smith, J. W., & Rozengurt, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057289 · Cited by 127
Metformin and neoplasia: Implications and indications
Aljada, A., & Mousa, S. A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.004 · Cited by 128
Metformin: An Emerging New Therapeutic Option for Targeting Cancer Stem Cells and Metastasis
Rattan, R., Fehmi, R.-A., & Munkarah, A. R. (2012) · Journal of Oncology · doi:10.1155/2012/928127 · Cited by 126
Phenformin as an Anticancer Agent: Challenges and Prospects
Rubiño, M. E. G., Carrillo, E., Ruiz-Alcalá, G., Domínguez‐Martín, A., Marchal, J. A., & Boulaiz, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133316 · Cited by 125
Diabetes and Cancer: Is Diabetes Causally Related to Cancer?
Suh, S., & Kim, K. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.193 · Cited by 122
Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression
Ng, C.-A. W., Jiang, A. A., Toh, E. M. S., Ng, C. H., Ong, Z. H., Peng, S., Tham, H. Y., Sundar, R., Chong, C. S., & Khoo, C. M. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03676-x · Cited by 114
Phenformin as prophylaxis and therapy in breast cancer xenografts
Appleyard, M. V. C. L., Murray, K. E., Coates, P. J., Wullschleger, S., Bray, S. E., Kernohan, N. M., Fleming, S., Alessi, D. R., & Thompson, A. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.56 · Cited by 108
Chen, T., Lin, C., Huang, P., & Wen, C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06664.x · Cited by 107
Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients
Sciacca, L., Vigneri, R., Tumminia, A., Frasca, F., Squatrito, S., Frittitta, L., & Vigneri, P. G. (2013) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.006 · Cited by 105
Campbell, C., Wang, T., McNaughton, A. L., Barnes, E. J., & Matthews, P. C. (2020) · Journal of Viral Hepatitis · doi:10.1111/jvh.13452 · Cited by 109
Metformin role in Parkinson’s disease: a double-sword effect
Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Ashour, N. A., Jabir, M. S., Negm, W. A., & Batiha, G. E. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04771-7 · Cited by 104
Sharma, P., & Kumar, S. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0398-0 · Cited by 102
Metadata
- Authors
- Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G.
- Affiliations
- Isala (NL)
- Diabetes Centre, Isala Clinics, Zwolle, the Netherlands;
- University Medical Center Groningen (NL)
- Corresponding author
- Landman, Gijs W.D.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-11-16
- Volume
- 33
- Issue
- 2
- Pages
- 322-326
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2809274
- OpenAlex
- W2058725063
- Cited by
- 502
- References
- 20
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 11 · 2023: 17 · 2022: 28 · 2021: 24 · 2020: 31 · 2019: 23 · 2018: 28 · 2017: 30 · 2016: 25 · 2015: 39 · 2014: 41 · 2013: 54 · 2012: 48
- FWCI
- 18.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, cancer mortality, type 2 diabetes, diabetes drugs, cancer risk, standardized mortality ratio
- MeSH terms
- Aged, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Neoplasms, Netherlands, Prospective Studies, Risk Factors, Smoking, Cohort Studies, Body Mass Index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
